Royalty Report: Drugs, Disease, Therapeutic – Collection: 28511


Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 3


This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 3

Primary Industries

  • Drugs
  • Disease
  • Therapeutic
  • Pharmaceuticals
  • cardiac
  • Cancer

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 28511

License Grant
Under the Agreement, the parties agreed to collaborate to develop and commercialize products in the field described as autologous skeletal myoblasts for cardiac therapy (and conditionally allogenic skeletal myoblasts for cardiac therapy) in Japan and such other Asian countries as the parties may agree. Pursuant to the Agreement, the Licensee has an exclusive, royalty-bearing License, with a limited right to grant subLicenses, under certain technology and patent rights controlled by the Licensor; and a non-exclusive, non-royalty bearing right and License to use certain data resulting from clinical trials for products based on the Licensed technology and patent rights for purposes of seeking regulatory approvals. The Agreement specifies the rights and obligations of the parties with respect to collaboration and development of products covered by the Agreement. In May 2008, the Licensee exercised an option to extend a milestone for one year for $300,000. The milestone consisted of a Phase I clinical trial for the Myoblast Program in Japan and was extended for two years.
Field of Use
The rights granted apply to the medical industry.

IPSCIO Record ID: 6512

License Grant
Under the Agreement, the Licensee has a worldwide, non-exclusive right and License under certain specified patent rights, with the right to subLicense, to make, have made, use, have used, offer for sale, sell, lease, import and/or otherwise dispose of products in the field of use.
Field of Use
The rights granted relate in the field described as cell-transplantation treatments and related therapies that use genetically unmodified skeletal myoblasts for the treatment of cardiovascular disease.

IPSCIO Record ID: 101938

License Grant
A wholly-owned subsidiary of the parent company entered into a Collaboration, License and Option Agreement with Licensee to discover, develop and commercialize small molecule antagonists for immuno-oncology and precision oncology targets.
License Property
Under the Collaboration Agreement, Licensor has the responsibility for conducting all discovery and preclinical activities, including Investigational New Drug (IND) enabling studies and providing Phase 1 clinical trial supply, and Licensee is responsible for all clinical development, regulatory and commercialization efforts worldwide, excluding India and Russia. The Collaboration Agreement provides that the parties will collaborate exclusively in immuno-oncology for an initial period of approximately two years, with the option for Licensee to extend the broad immuno-oncology exclusivity.
Field of Use
This agreement pertains to the drug industry.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.